Evaluation of Serum Taurine as a Prognostic Marker for Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant

Taurine Clinical Trial

— Taurine/LDLT  

Official title:

Evaluation of Serum Taurine as a Prognostic Marker for Graft Function in Adult Egyptian Patients Undergoing Living Donor Liver Transplant : A Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04047043
• Other study ID #: IRB 0006379
• Status: Completed
• Start date: August 1, 2019
• Est. completion date: May 30, 2020

Study information

• Verified date: August 2020
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Although the hepatoprotective properties of taurine are well established, however the correlation of the perioperative serum level of this amino acid in the recipients of living donor liver transplantation ( LDLT ) and graft function has not been investigated so far. In the present study, we proposed to examine the serum taurine as a prognostic marker for graft function in adult Egyptian patients undergoing LDLT

Description:

• All selected adult patients undergoing LDLT will be admitted to the ICU post LDLT

• Preoperative assessment and preparation will be done according to the standard protocol of the hospital. After full clinical examinations using MELD score corrected for serum sodium level ), imaging techniques (Abdominal U.S; abdominal triphasic CAT Scan, liver biopsy, CT volumetry, upper and lower GIT endoscopy, CT chest, bone scan in HCC patients, renal scan in patients with urinary creatinine clearance < 60 ml/min), pulmonary function test, carotid duplex and dobutamine ECHO will be done for all recipients .

• Serum level of AST, ALT, bilirubin, albumin, ALP, GGT, prothrombin, INR, partial thrombin time, factor V, fasting blood glucose, CBC, CRP, Procalcitonin, urea, creatinine, urinary creatinine clearance, serum electrolytes, urine and stool analysis will be done for all patients.

• Analysis of serum levels of specific liver tumor markers including AFP, beside taurine as a possible new marker will be done for all patients .

• HCV and HBV will be detected for all patients by PCR technique.

• CMV IgM , EBV IgM ,HSV IgM will be done for all patients.

• After 12 hours fasting, 10 ml of venous blood will be collected, in plain tube and allowed to clot for 1/2 an hour. Then, it will be centrifuged at 3,000 rpm for 10 min. The serum will be separated and stored at -20 Cº to avoid loss of biological activity until the batch analysis for serum taurine which will be measured four times for the recipient ( preoperative before induction of anesthesia , 7, 14 days and 30 days post transplant ) by high performance liquid chromatography (HPLC) .

Recipient patients will be divided into 3 groups according to preoperative serum taurine .

• Group 1 ( > 30 μmol/L) (20 cases)

• Group 2 (30-20 μmol/L) (20 cases)

• Group 3 (< 20 μmol/L ) (20 cases)

Intraoperatively, both standard anesthetic and piggyback techniques for hepatic transplantation will be performed by the same anesthesia and surgical team who will be blinded to study medication. Intraoperative blood loss, graft weight, graft weight to recipient weight ratio (GWRWR), blood products transfused, and intraoperative adverse events will be recorded. At the end of surgery, patients will be transferred to the ICU and will be monitored and receive the standard protocol for postoperative management after liver transplantation .

All patients will be assessed for primary graft function (PGF) on a daily basis during the first week post-transplant. Primary graft dysfunction includes one or more of the following variables: (1) bilirubin ≥10 mg/dL on postoperative day 7; (2) INR ≥1.6 on postoperative day 7; and (3) ALT or AST >2000 IU/L within 7 postoperative days.

The primary outcome include correlation between serum taurine levels ( μmol/L) of recipients and graft function which will be detected by liver profile. Secondary outcomes include 30 days mortality (days), the duration of ICU and hospital stays (days) and any recorded post operative complications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: May 30, 2020
• Est. primary completion date: May 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Recipient age =18 years.

• Donor age between 18 and 45 years

• ABO group compatibility with the recipient

• Normal psychological workup.

Exclusion Criteria:

• Recipients patients with pre-existing renal failure requiring hemodialysis or continuous hemofiltration, glomerular filtration rate = 30 ml /min by renal scan, ..

• Re-transplant

• HA1C > 7%

• Pregnancy.

• Donors with fatty liver.

• Estimated remnant liver volume for donor is < 30% of total liver volume.

• Donor body mass index > 28 kg/m².

• Donor with abnormal biliary anatomy.

• Donor with steatosis > 10%.

Related Conditions & MeSH terms

• Taurine

Intervention

Diagnostic Test:
• serum taurine
blood sample for serum taurine level

Locations

Country	Name	City	State
Egypt	Hanaa El Gendy	Cairo	Ain Shams University Specialized Hospital

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Taurine level in micro mol/L	Taurine level preoperative, 7th,14 th and 30 days post liver transplantation will be assesd and correlated with graft function	7 months
Secondary	Seventh day syndrome, 30 days mortality (days), the duration of ICU and hospital stays (days).	Taurine level will be correlated with these parameters	7 months